ALX ONCOLOGY HOLDINGS INC Amortization of Debt Issuance Costs and Discounts
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Amortization of Debt Issuance Costs and Discounts of $134.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC amortization of debt issuance costs and discounts for the quarter ending 2026-06-30 was $66.00K, a 4.35% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC amortization of debt issuance costs and discounts for the quarter ending 2026-03-31 was $68.00K, a 1.49% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC amortization of debt issuance costs and discounts for the quarter ending 2025-12-31 was $72.00K, a 4.35% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC amortization of debt issuance costs and discounts for the quarter ending 2025-09-30 was $72.00K, a 9.09% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC amortization of debt issuance costs and discounts for fiscal 2025 was $280.00K, a 5.66% increase from fiscal 2024.
- ALX ONCOLOGY HOLDINGS INC amortization of debt issuance costs and discounts for fiscal 2024 was $265.00K, a 6.00% increase from fiscal 2023.
- ALX ONCOLOGY HOLDINGS INC amortization of debt issuance costs and discounts for fiscal 2023 was $250.00K, a 468.18% increase from fiscal 2022.
- ALX ONCOLOGY HOLDINGS INC amortization of debt issuance costs and discounts for fiscal 2022 was $44.00K.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2026-06-30 | $66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $134.00K 10-Q · filed 2026-08-06 | $206.00K derived: sum of 3 quarters · filed 2026-08-06 | $278.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $68.00K 10-Q · filed 2026-05-08 | $140.00K derived: sum of 2 quarters · filed 2026-05-08 | $212.00K derived: sum of 3 quarters · filed 2026-05-08 | $281.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $144.00K derived: sum of 2 quarters · filed 2026-03-09 | $213.00K derived: sum of 3 quarters · filed 2026-08-06 | $280.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | $72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $141.00K derived: sum of 2 quarters · filed 2026-08-06 | $208.00K 10-Q · filed 2025-11-07 | $277.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $69.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $136.00K 10-Q · filed 2026-08-06 | $205.00K derived: sum of 3 quarters · filed 2026-08-06 | $271.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $67.00K 10-Q · filed 2026-05-08 | $136.00K derived: sum of 2 quarters · filed 2026-05-08 | $202.00K derived: sum of 3 quarters · filed 2026-05-08 | $268.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $135.00K derived: sum of 2 quarters · filed 2026-03-09 | $201.00K derived: sum of 3 quarters · filed 2026-03-09 | $265.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $66.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $132.00K derived: sum of 2 quarters · filed 2025-11-07 | $196.00K 10-Q · filed 2025-11-07 | $260.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $130.00K 10-Q · filed 2025-08-12 | $194.00K derived: sum of 3 quarters · filed 2026-03-09 | $257.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | $64.00K 10-Q · filed 2025-05-08 | $128.00K derived: sum of 2 quarters · filed 2026-03-09 | $191.00K derived: sum of 3 quarters · filed 2026-03-09 | $253.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | $64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $127.00K derived: sum of 2 quarters · filed 2026-03-09 | $189.00K derived: sum of 3 quarters · filed 2026-03-09 | $250.00K 10-K · filed 2026-03-09 |
| 2023-09-30 | $63.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $125.00K derived: sum of 2 quarters · filed 2024-11-07 | $186.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $123.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $61.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $44.00K 10-K · filed 2025-03-06 | |||
| 2020-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $200.00K derived: sum of 2 quarters · filed 2023-03-09 | $313.00K derived: sum of 3 quarters · filed 2023-03-09 | $421.00K 10-K · filed 2023-03-09 |
| 2020-09-30 | $118.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $231.00K derived: sum of 2 quarters · filed 2021-11-12 | $339.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $221.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $108.00K 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $11.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |